Blood
Articles in this Issue
Glofitamab effectively bridging CD19-specific CAR T- cell therapy while maintaining safety in patients with refractory DLBCL
Abstract Glofitamab, a bispecific antibody targeting CD20 and CD3, is approved for relapsed/refractory diffuse large B-cell lymphoma (r/r DL...
Comparative efficacy and safety of ruxolitinib and remestemcel-l in the treatment of steroid-refractory acute graft-versus-host disease: Systematic review and meta-analysis
Abstract Introduction: Steroid-refractory acute graft-versus-host disease (SR-aGVHD) remains a significant post-transplant challenge, often...
Efficacy and safety of polatuzumab vedotin–based regimens in newly diagnosed diffuse large B-cell lymphoma: A single-center retrospective study
Abstract Objective To evaluate the efficacy and safety of polatuzumab vedotin (Pola)–based regimens in newly diagnosed diffuse large B-cell...
Safety and preliminary efficacy of anti-CD19 CAR T cells zorpocabtagene-autoleucel in systemic autoimmune diseases: Final analysis of the castle trial
Abstract Introduction: Autoimmune diseases (AID) such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and idiopathic inflamm...
The prognostic value of JAK2V617F burden for discontinuation of interferon-α2 in patients with myeloproliferative neoplasms
Abstract Background: Myeloproliferative neoplasms (MPNs) are characterized by clonal proliferation of myeloid cells, driven by somatic mutati...
FVIII-associated LDL circulates longer and participates in blood clot formation
Abstract Background and rationale. Hemophilia A is a bleeding disorder caused by deficient or absent in coagulation factor VIII (FVIII). Sev...
First-line therapy with rituximab vs. rituximab-CHOP in post-transplant monomorphic diffuse large B-cell lymphoma (DLBCL): Long-term real-world evidence from the spanish group of lymphoma (GELTAMO)
Abstract Introduction: Post-transplant lymphoproliferative disorders (PTLD) are a heterogeneous group of immunosuppression-related conditions...
BAFFR-CAR T cells (PMB-CT01) demonstrate durable responses and manageable toxicities in relapsed/refractory B-cell lymphomas with prior CD19-directed therapy failure or CD19-negative disease
Abstract Introduction: CD19-directed CAR T cell therapies have redefined treatment paradigms for B-cell malignancies. However, relapse is co...
Luspatercept initiated at the maximum-approved dose in transfusion-dependent lower-risk myelodysplastic syndromes: Interim analysis from maxilus
Abstract Background: Luspatercept is an erythroid-maturation agent approved to treat anemia in patients (pts) with trans...
Risk of thrombosis in multiple myeloma patients treated with carfilzomib-based regimens: A systematic review and meta-analysis of clinical trials
Abstract Background: Carfilzomib is a second-generation, irreversible proteasome inhibitor approved for treatment of multiple myeloma (MM). I...
Comparative disproportionality analysis of cytokine release syndrome associated with FDA-approved bispecific T-cell engagers in relapsed/refractory multiple myeloma
Abstract Introduction:Bispecific T-cell engagers (BiTEs) are an important immunotherapeutic option for patients with relapsed/refractory mul...
A phase II study of acalabrutinib in combination with R-CHOP for previously untreated transplant-ineligible mantle cell lymphoma patients in Spain (the SOUND-MCL Study)
Abstract Background and Significance Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy for which more effective therapeutic appr...
Clinical burden and predictors of cytokine release syndrome in CAR-T cell therapy for hematologic malignancies: Insights from a national cohort
Abstract Background: Cytokine release syndrome (CRS) is a frequent and potentially life-threatening complication of CAR-T cell therapy. Whil...
Refining thrombotic risk stratification in essential thrombocythemia: Impact of european leukemia net clinical signs and symptoms in patients treated with hydroxyurea
Abstract Introduction Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm characterized by an increased risk of thromboti...
MLL3 and MLL4 maintain hematopoietic stem cell multipotency by actively opposing a B-cell default state
Abstract Hematopoietic stem cells (HSCs) and multipotent progenitors (MPPs) reside in multipotent states and are capable of giving rise to m...
Characteristics of diffuse large B-cell Lymphoma patients with rituximab induced acute thrombocytopenia
Abstract Background: Rituximab is a monoclonal antibody that targets CD20-positive B cells. Its combination with the CHO...
Clinical, molecular, and demographic features of systemic mastocytosis: Analysis of a large cohort
Abstract Introduction Systemic Mastocytosis (SM) is a rare and clinically heterogeneous myeloid neoplasm defined by clonal mast cell accumula...
Unstructured serum electrophoresis data limits real world AI models in multiple myeloma: Evaluation of 384 institutions across United States
Abstract The monoclonal protein or M-spike remains a cornerstone of clinical decision-making in multiple myeloma (MM), serving as a key biom...
Predictors of discordant end-of-treatment PET positivity in advanced-stage classical Hodgkin lymphoma patients with negative interim PET response
Abstract Background In advanced-stage classical Hodgkin lymphoma (cHL), achieving a negative interim PET (iPET) after two cycles of ABVD is...
High variation of inpatient admission rates between hospitals for cancer-associated pulmonary embolism in California
Abstract Introduction Patients with pulmonary embolism (PE) at low or very low risk for 30-day mortality by risk prediction scores such as t...
Venetoclax combined with three-day multi-frequency Decitabine (DEC3-VEN) in the treatment of adult patients with de novo Acute Myeloid Leukemia：updated results of a phase II trial
Abstract Background: Venetoclax (VEN), a selective small-molecule inhibitor of BCL-2, has shown significant improvements...
PRMT5 is a therapeutic vulnerability in cutaneous T-cell lymphoma
Abstract Background: Cutaneous T-cell Lymphoma (CTCL) is a type of T-cell non-Hodgkin's lymphoma generally localized to the skin. Novel, mor...
CAC-MM-001: Anti-BCMA CAR-T therapy followed by autologous stem cell transplantation and second CAR-T (CART-ASCT-CART2) in newly diagnosed multiple myeloma patients with P53 gene abnormalities.
Abstract Introduction: Despite notable advancements in treatments that have improved overall survival, patients with mul...
Hematologic predictors of serious infection and impact of serious infection on long-term mortality in AML patients: Insights from propensity-matched real-world cohorts
Abstract Background: Acute Myeloid Leukemia (AML) imposes a significant clinical burden, with an estimated 22,010 new diagnoses and 11,090 d...
Retrospective analysis of treatment outcome and complications of young patients (less than 41 years old) with multiple myeloma among patients treated at king faisal specialist hospital & research center jeddah in the period 2011 to 2024, a single center experience
Abstract Background: Multiple Myeloma (MM) is a Hematological malignancy of B-cell plasma cell that affects elderly population. It is the se...